slides · global inventory
Image
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 119,566
Current window 74,611-74,640
Pages 3,986
Rows per page 30
Component
74,611-74,640 of 119,566
85
Slide provides a structured breakdown of business segments with associated KPIs and competitive landscape.LSE | Investor Day Presentation Deck | 100 slides · LSEG
Conference presentation Investor relations 1 hit
87
The diagram uses a hub-and-spoke/process hybrid to link lifecycle stages to specific risk domains and product brands.LSE | Investor Day Presentation Deck | 100 slides · LSEG
Conference presentation Investor relations 1 hit
91
The slide uses a vertical flow diagram to show how partnerships contribute to different layers of the business.LSE | Investor Day Presentation Deck | 100 slides · LSEG
Conference presentation Investor relations 1 hit
96
LSE | Investor Day Presentation Deck | 100 slidesLSE | Investor Day Presentation Deck | 100 slides · LSEG
Conference presentation Investor relations 1 hit
100
LSE | Investor Day Presentation Deck | 100 slidesLSE | Investor Day Presentation Deck | 100 slides · LSEG
Conference presentation Investor relations 1 hit
01
Mainz Biomed NV | Investor Presentation Deck | 23 slidesMainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
02
Mainz Biomed NV | Investor Presentation Deck | 23 slidesMainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
05
The slide uses a split-layout comparing the company's mission/context on the left with the specific product value proposition and market statistics on the right.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · Problem1 hit
06
Mainz Biomed NV | Investor Presentation Deck | 23 slidesMainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · Agitate1 hit
10
Includes logos of four partner organizations.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
11
The slide uses a bulleted list to detail the partnership strategy, focusing on leveraging existing lab infrastructure to minimize marketing overhead.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
13
Includes a stock market snapshot of Exact Sciences and a clinical performance comparison table.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
14
Includes a disclaimer at the bottom and a product visualization.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
19
Mainz Biomed NV | Investor Presentation Deck | 23 slidesMainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
21
Includes a disclaimer at the bottom and a citation for the 85% detection rate.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
23
The slide includes a specific milestone criterion for February 2022 regarding biomarker specificity.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
01
Features a molecular structure visualization.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
06
Uses a before-after-bridge framework to contrast existing therapy failure with Nuvalent's solution.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Beat · Problem1 hit
10
The slide features a 3D molecular rendering showing the inhibitor (pink) bound to the target protein (blue).Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
14
The slide uses a medical illustration to map specific TRK receptor inhibition (TRKB, TRKC, TRKA) to corresponding neurological and physiological side effects.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Beat · Competition1 hit
15
The slide uses a structured table-like layout to define the product profile.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
21
The slide uses bioluminescence imaging to show tumor reduction and a Kaplan-Meier survival curve to show efficacy.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
25
The slide uses a three-column process flow to explain the biological mechanism of ALK-driven cancer and resistance.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
28
The slide uses a structured table format to define the product's key performance characteristics.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
34
Nuvalent | IPO Presentation Deck | 40 slidesNuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
37
Nuvalent | IPO Presentation Deck | 40 slidesNuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
39
The slide features a 3D molecular structure visualization, likely a protein-ligand complex.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
04
Uses a 'What if' rhetorical device to frame the company's core technological thesis.Omega Therapeutics | IPO Presentation Deck | 33 slides · Omega Therapeutics
Pitch deck Investment bank 1 hit
06
Uses a biological analogy of an 'operating system' to explain gene regulation.Omega Therapeutics | IPO Presentation Deck | 33 slides · Omega Therapeutics
Pitch deck Investment bank 1 hit
08
The slide depicts a biological mechanism involving DNA structure and protein interaction, likely related to gene regulation.Omega Therapeutics | IPO Presentation Deck | 33 slides · Omega Therapeutics
Pitch deck Investment bank 1 hit